RSS | Login | Register

UNASYN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare UNASYN to:

Generic Name for UNASYN

Ampicillin sodium 1g, sulbactam sodium 0.5g (1.5g vial); or ampicillin sodium 2g, sulbactam sodium 1g (3g vial); IM or IV inj; sodium content 5mEq/g of ampicillin.

Legal Classification:

Pharmacological Class for UNASYN

Broad-spectrum penicillin + β-lactamase inhibitor.

Manufacturer of UNASYN

Pfizer Labs

Indications for UNASYN

Susceptible skin and skin structure, intraabdominal, gynecologic infections.

Adult dose for UNASYN

Dose is given as ampicillin + sulbactam. Normal renal function (CrCl ≥30mL/min): 1.5–3g IM or IV every 6 hours; CrCl 15–29mL/min: 1.5–3g every 12 hrs; CrCl 5–14mL/min: 1.5–3g every 24 hrs.

Children's dosing for UNASYN

Intraabdominal infections: not recommended. Dose is given as ampicillin + sulbactam. <1yr: not recommended. ≥1yr (<40kg): 300mg/kg per day IV in equally divided doses every 6 hrs; usual max 14 days. ≥40kg: as adult.

Warnings/Precautions for UNASYN

Cephalosporin, imipenem, other allergy or mononucleosis: not recommended. Pregnancy (Cat.B). Nursing mothers.

Interactions for UNASYN

Potentiated by probenecid. Increased incidence of rash with allopurinol. May cause false (+) Clinitest, Benedict's or Fehling's soln.

Adverse Reactions for UNASYN

Inj site reactions, diarrhea, rash, blood dyscrasias, anaphylaxis, elevated liver enzymes.

How is UNASYN supplied?

Vials (1.5g, 3g)—1

Related Disease:

Infections, bacterial~systemic antiinfectives

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.